en · de · es · fr · pt
melanotan-2-notes.peptides9000.com › Wiki › Melanotan-2 Identity And Receptor Pharmacology — Practical Notes

Melanotan-2 Identity And Receptor Pharmacology — Practical Notes

By Editorial Desk · published 2025-12-11 · last reviewed 2025-12-25 · Wiki

Everything below concerns alpha-MSH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 Structure and Receptor Pharmacology

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Melanotan-2 at a glance

PropertyValueNotes
Common synonymsMelanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amideNaming follows peptide convention; the numeral distinguishes it from melanotan-1
Molecular formulaC50H69N15O9Includes the lactam bridge; no counter-ion assumed
Monoisotopic mass1023.53 DaFree base; salts and counter-ions shift the observed value
AppearanceWhite to off-white lyophilised powderBatch-to-batch colour variation is not itself proof of impurity
Typical analytical methodRP-HPLC purity determination with ESI-MS identity confirmationRetention time alone does not establish sequence identity

Identity and Chemical Background

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Related pages on this site

Background from the literature

Prior to the development of biological therapy as a modality to treat IBD, other medications that modulate the immune system—including 5-aminosalicylates, steroids, azathioprine, and other immunosuppressants—were primarily used in treatment. Corticosteroids are effective in inducing clinical remission in patients with active IBD, but they can't be used long term due to the risk of steroid-dependence and harsh side effects. The other medications like 5-aminosalicylates and azathioprine are often used to reduce steroid use while maintaining remission, but their actual effect on the state of the disease and the need for surgery remains unknown. Patients with Crohn's disease that developed complications, including fistulae (= abnormal connections to the bowel) were treated with surgery. Patients with ulcerative colitis who do not respond to medications are still treated with colectomy (= removal of the colon). However, basic science research showed that many cytokines were elevated in both Crohn's disease and ulcerative colitis. Crohn's disease cytokines are of the type 1 (Th1) cytokines, which include TNF-α, interleukin-2, and interferon γ. Ulcerative colitis was less conclusively linked to the production of Th2 cytokines. TNF inhibiting biological therapies were initially used in IBD patients who weren't responding to conventional therapy. They proved to be very effective in some patients, shifting treatment goals from simply improving symptoms to actually changing the course of the disease by reversing mucosal inflammation and preventing long-term complications and surgery.

Another method of end group removal for the thiocarbonyl containing end-groups of RAFT polymers is the addition of heat to the polymer; this is referred to as thermolysis. One method of monitoring thermolysis of RAFT polymers is by thermogravimetric analysis resulting in a weight-loss of the end group. An advantage of this technique is that no additional chemicals are required to remove the end group; however, it is required that the polymer be thermally stable to high temperature and therefore may not be effective for some polymers. Depending on the polymers sensitivity to ultraviolet radiation (UV) it has been reported in recent years that decomposition of end-groups can be effective, but preliminary data suggest that decomposition by UV leads to a change in the distribution of molecular weights of the polymer.

Supermarkets make up for their low margins by a high volume of sales, and with sales of higher-margin items bought by the customers. Self-service with shopping carts (trolleys) or baskets reduces labor costs, and many supermarket chains are attempting further reduction by shifting to self-service check-outs.

At atmospheric pressure, arsenic sublimes gradually upon heating, and sublimes rapidly at 887 K (614 °C). Cadmium and zinc sublime much more than other common materials, so they are not suitable materials for use in vacuum.

The 1981 Springboks tour of New Zealand was compromised by demonstrations, and the tourists had to be kept under strict security throughout their visit. Two games had to be cancelled. The game at Hamilton in the first week of the tour saw 200 protestors rip down a chain fence, sprinkle tacks all over the pitch and then staged a sit-in on the halfway line. At the time, a crowd of 25,000 was watching them playing Waikato. Subsequent matches saw the arrival of barbed wire, and police with batons. The match against South Canterbury at Timaru was cancelled because the authorities thought that they would not be able to control the demonstrations there. The final test of the tour was buzzed by a Cessna aircraft - some in fact nicknamed it the "Crazy Biggles Test". The plane continually strafed the pitch, and dropped flour bombs, flares and leaflets. All-Black prop Gary Knight was temporarily stunned by a flour bomb. Musician Bruce Russell received two police convictions as a student leader of protests against the tour. He was at the University of Otago at the time. It was a tight game, with Allan Hewson, the New Zealand full-back kicking a long range penalty to win the game 25–22. As Rod Chester and Nev McMillan described the scene:

Sources: en.wikipedia.org

Further detail

=== Substrate-like inhibitors === Substrate-like inhibitors (Figure 4) are more common than the non-substrate-likes. They bind either covalently or non-covalently and have a basic structure where the P1-substituent occupies the S1-pocket and the P2-substituent occupies the S2-pocket. Usually they contain a proline mimetic that occupies the S1-pocket. Large substituents on the 2-cyanopyrrolidine ring are normally not tolerated since the S1-pocket is quite small. Since DPP-4 is identical with the T-cell activation marker CD26 and DPP-4 inhibitors are known to inhibit T-cell proliferation, these compounds were initially thought to be potential immunomodulators. When the function against type 2 diabetes was discovered, the cyanopyrrolidines became a highly popular research material. A little later vildagliptin and saxagliptin, which are the most developed cyanopyrrolidine DPP-4 inhibitors to date, were discovered.

When newly opened, Viola flowers may be used to decorate salads or in stuffings for poultry or fish. Soufflés, cream, and similar desserts can be flavoured with essence of Viola flowers. The young leaves are edible raw or cooked as a mild-tasting leaf vegetable. The flowers and leaves of the cultivar 'Rebecca', one of the Violetta violets, have a distinct vanilla flavor with hints of wintergreen. The pungent perfume of some varieties of V. odorata adds inimitable sweetness to desserts, fruit salads, and teas while the mild pea flavor of V. tricolor combines equally well with sweet or savory foods, like grilled meats and steamed vegetables. The heart-shaped leaves of V. odorata provide a free source of greens throughout a long growing season, while the petals are used for fragrant flavoring in milk puddings and ice cream or in salads and as garnishes. A candied violet or crystallized violet is a flower, usually of Viola odorata, preserved by a coating of egg white and crystallised sugar. Alternatively, hot syrup is poured over the fresh flower (or the flower is immersed in the syrup) and stirred until the sugar recrystallizes and has dried. This method is still used for rose petals and was applied to orange flowers in the past (when almonds or orange peel are treated this way they are called pralines). Candied violets are still made commercially in Toulouse, France, where they are known as violettes de Toulouse. They are used as decorating cakes or trifles or included in aromatic desserts.

== History == In 2018, three unrelated children who had similar symptoms of developmental delays, skeletal abnormalities, and mild dysmorphic facial features. The first patient had an autism diagnosis and mild skeletal abnormalities but was otherwise normal. The second patient had poor growth in infancy, difficulty walking, tremors, difficulty speaking, and needed to be homeschooled due to academic difficulties. The third patient had microcephaly, poor growth, and was slow to learn how to walk but was able to attend mainstream school. All three of these patients had a variety of dysmorphic facial features that none of the patients shared except for a prominent nose, wide mouth, and thin upper lip. They were identified as having a de novo mutation on their QRICH1 gene. In 2019, 2 unrelated children were identified as having VERBAS and were found to have subtle chondrodysplasia. In 2021, Fohrenbach et al. described 4 unrelated patients with VERBAS. One patient, a three-year-old, developed nephroblastoma and died from complications, suggesting that increased cancer risk may be a part of the syndrome. In 2023, a 17-year-old girl was suffering from seizures and leukodystrophy. The girl had a history of minor developmental delays and was thought to have a perinatal brain injury resulting in mild right-side paresis. Her mother shared similar dysmorphic facial features, short stature, and distractable nature, causing them to be referred to a genecist. It was discovered that they both carried a novel QRICH1-related mutation and were diagnosed with VERBRAS.

The courts give the EU a wide discretion to implement policy, so judicial review is possible only if agricultural measures are 'manifestly inappropriate'. EU law does not yet have a systematic plan or subsidies to rewild depleted environments, and to move to complete clean energy infrastructure.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

How does it differ from the natural hormone?

The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.

Does it hold any regulatory approval?

No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

Network